359 related articles for article (PubMed ID: 28669410)
1. Thrombin activatable fibrinolysis inhibitor (TAFI) - A possible link between coagulation and complement activation in the antiphospholipid syndrome (APS).
Grosso G; Vikerfors A; Woodhams B; Adam M; Bremme K; Holmström M; Ågren A; Eelde A; Bruzelius M; Svenungsson E; Antovic A
Thromb Res; 2017 Oct; 158():168-173. PubMed ID: 28669410
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibodies targeting the antifibrinolytic activity of activated thrombin-activatable fibrinolysis inhibitor but not the anti-inflammatory activity on osteopontin and C5a.
Semeraro F; Ammollo CT; Gils A; Declerck PJ; Colucci M
J Thromb Haemost; 2013 Dec; 11(12):2137-47. PubMed ID: 24134522
[TBL] [Abstract][Full Text] [Related]
3. Increase in plasma thrombin-activatable fibrinolysis inhibitor may not contribute to thrombotic tendency in antiphospholipid syndrome because of inhibitory potential of antiphospholipid antibodies toward TAFI activation.
Ieko M; Yoshida M; Naito S; Nakabayashi T; Kanazawa K; Mizukami K; Mukai M; Atsumi T; Koike T
Int J Hematol; 2010 Jun; 91(5):776-83. PubMed ID: 20490730
[TBL] [Abstract][Full Text] [Related]
4. Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation.
Antovic JP; Blombäck M
Thromb Res; 2002 Apr; 106(1):59-62. PubMed ID: 12165290
[TBL] [Abstract][Full Text] [Related]
5. Thrombin activatable fibrinolysis inhibitor (TAFI): a molecular link between coagulation and fibrinolysis.
Miljić P; Heylen E; Willemse J; Djordjević V; Radojković D; Colović M; Elezović I; Hendriks D
Srp Arh Celok Lek; 2010 Jan; 138 Suppl 1():74-8. PubMed ID: 20229688
[TBL] [Abstract][Full Text] [Related]
6. Thrombin-activatable fibrinolysis inhibitor.
Marx PF
Curr Med Chem; 2004 Sep; 11(17):2335-48. PubMed ID: 15379716
[TBL] [Abstract][Full Text] [Related]
7. Reduced fibrinolytic resistance in patients with factor XI deficiency. Evidence of a thrombin-independent impairment of the thrombin-activatable fibrinolysis inhibitor pathway.
Colucci M; Incampo F; Cannavò A; Menegatti M; Siboni SM; Zaccaria F; Semeraro N; Peyvandi F
J Thromb Haemost; 2016 Aug; 14(8):1603-14. PubMed ID: 27094709
[TBL] [Abstract][Full Text] [Related]
8. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation.
Myles T; Nishimura T; Yun TH; Nagashima M; Morser J; Patterson AJ; Pearl RG; Leung LL
J Biol Chem; 2003 Dec; 278(51):51059-67. PubMed ID: 14525995
[TBL] [Abstract][Full Text] [Related]
9. Thrombin activatable fibrinolysis inhibitor and clot lysis time in pregnant patients with antiphospholipid syndrome: relationship with pregnancy outcome and thrombosis.
Martinez-Zamora MA; Tassies D; Carmona F; Espinosa G; Cervera R; Reverter JC; Balasch J
Am J Reprod Immunol; 2009 Dec; 62(6):381-9. PubMed ID: 19895374
[TBL] [Abstract][Full Text] [Related]
10. Insights into thrombin activatable fibrinolysis inhibitor function and regulation.
Foley JH; Kim PY; Mutch NJ; Gils A
J Thromb Haemost; 2013 Jun; 11 Suppl 1():306-15. PubMed ID: 23809134
[TBL] [Abstract][Full Text] [Related]
11. Structure-function relationships in thrombin-activatable fibrinolysis inhibitor.
Plug T; Meijers JC
J Thromb Haemost; 2016 Apr; 14(4):633-44. PubMed ID: 26786060
[TBL] [Abstract][Full Text] [Related]
12. Effect of warfarin treatment on thrombin activatable fibrinolysis inhibitor (TAFI) activation and TAFI-mediated inhibition of fibrinolysis.
Incampo F; Carrieri C; Galasso R; Scaraggi FA; Di Serio F; Woodhams B; Semeraro N; Colucci M
J Thromb Haemost; 2013 Feb; 11(2):315-24. PubMed ID: 23256818
[TBL] [Abstract][Full Text] [Related]
13. Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles.
Boffa MB; Koschinsky ML
Clin Biochem; 2007 Apr; 40(7):431-42. PubMed ID: 17331488
[TBL] [Abstract][Full Text] [Related]
14. Clot lysis time and thrombin activatable fibrinolysis inhibitor in severe preeclampsia with or without associated antiphospholipid antibodies.
Martínez-Zamora MA; Tassies D; Carmona F; Espinosa G; Cervera R; Reverter JC; Balasch J
J Reprod Immunol; 2010 Nov; 86(2):133-40. PubMed ID: 20594598
[TBL] [Abstract][Full Text] [Related]
15. Increased zymogen activity of thrombin-activatable fibrinolysis inhibitor prolongs clot lysis.
Mishra N; Buelens K; Theyskens S; Compernolle G; Gils A; Declerck PJ
J Thromb Haemost; 2012 Jun; 10(6):1091-9. PubMed ID: 22498006
[TBL] [Abstract][Full Text] [Related]
16. Thrombin-activable fibrinolysis inhibitor zymogen does not play a significant role in the attenuation of fibrinolysis.
Foley JH; Kim P; Nesheim ME
J Biol Chem; 2008 Apr; 283(14):8863-7. PubMed ID: 18252711
[TBL] [Abstract][Full Text] [Related]
17. Thrombin-activatable fibrinolysis inhibitor (TAFI) is enhanced in major trauma patients without infectious complications.
Relja B; Lustenberger T; Puttkammer B; Jakob H; Morser J; Gabazza EC; Takei Y; Marzi I
Immunobiology; 2013 Apr; 218(4):470-6. PubMed ID: 22749979
[TBL] [Abstract][Full Text] [Related]
18. Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin-activatable fibrinolysis inhibitor activation and activated thrombin-activatable fibrinolysis inhibitor activity.
Zhou X; Weeks SD; Ameloot P; Callewaert N; Strelkov SV; Declerck PJ
J Thromb Haemost; 2016 Aug; 14(8):1629-38. PubMed ID: 27279497
[TBL] [Abstract][Full Text] [Related]
19. Demonstration of enhanced endogenous fibrinolysis in thrombin activatable fibrinolysis inhibitor-deficient mice.
Mao SS; Holahan MA; Bailey C; Wu G; Colussi D; Carroll SS; Cook JJ
Blood Coagul Fibrinolysis; 2005 Sep; 16(6):407-15. PubMed ID: 16093731
[TBL] [Abstract][Full Text] [Related]
20. Total thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and pro-TAFI in patients with haemophilia A.
Antovic J; Schulman S; Eelde A; Blombäck M
Haemophilia; 2001 Nov; 7(6):557-60. PubMed ID: 11851753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
